HomeAI · summaries
Storia in 3 fonti
Gland Pharma inks strategic CDMO deal with global pharma firm, eyes $90-100 million annual revenue
Gland Pharma has signed a strategic Manufacturing and Supply Agreement with a leading global pharmaceutical company for technology transfer, manufacturing and supply of sterile injectable products. The agreement covers 55 SKUs across three sites, with annualised revenue potential of $90-100 million upon commercialisation. Revenue generation is expected to begin in 2029.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Gland Pharma inks strategic CDMO deal with global pharma firm, eyes $90-100 million annual revenue
Gland Pharma has signed a strategic Manufacturing and Supply Agreement with a leading global pharmaceutical company for technology transfer, manufacturing and supply of sterile…
- ·
thehindubusinessline.com
Gland Pharma net profit rises 47% to ₹317 crore in Q1
Strong performance driven by product launches and robust demand in CDMO segment, signaling a promising outlook for the fiscal year ahead
